Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Long-Term Data for First-Line RYBREVANT® and Lazertinib Show Median PFS Not Reached in EGFR-Mutated NSCLC

    Long-Term Data for First-Line RYBREVANT® and Lazertinib Show Median PFS Not Reached in EGFR-Mutated NSCLC

    June 4, 2023
    June 4, 2023

    Download the PDF